Targets › DPEP1
3 programs from 3 companies in 3 trials: 3 Phase 2; Genitourinary, Cardiovascular, Oncology; next expected readout Mar 2027.
Hydrolyzes a wide range of dipeptides including the conversion of leukotriene D4 to leukotriene E4. Hydrolyzes cystinyl-bis-glycine (cys-bis-gly) formed during glutathione degradation. (UniProt, P16444)
Open in Phaseline: the race on DPEP1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Arch Biopartners | LSALT Peptide Binds to dipeptidase-1 (DPEP1) and inhibits leukocyte recruitment | DPEP1 | Phase 2 | Acute Kidney Injury | Mar 2027 |
| Matthew James | Cilastatin Renal dipeptidase inhibitor | DPEP1 | Phase 2 | Acute Kidney Injury | Dec 2027 |
| Hospital General Universitario Gregorio Marañon | cilastatin Renal dipeptidase inhibitor | DPEP1 | Phase 2 | Debulking Surgery for Ovarian Cancer | Oct 2028 |
Acute Kidney Injury (2) Debulking Surgery for Ovarian Cancer (1)
protein or peptide (2), small molecule (1)
Matthew James (1) Arch Biopartners (1) Hospital General Universitario Gregorio Marañon (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.